Welcome to our dedicated page for Replimune Group SEC filings (Ticker: REPL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Replimune Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Replimune Group's regulatory disclosures and financial reporting.
Replimune Group, Inc.’s Chief Commercial Officer Christopher Sarchi reported an open-market sale of 8,626 shares of common stock at a weighted average price of $5.08 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations tied to a partial vesting of his restricted stock units under an irrevocable “sell to cover” provision, meaning the transaction was not a discretionary sale. After this tax-related sale, Sarchi directly holds 192,962 shares of Replimune common stock.
Replimune Group, Inc. director Philip Astley-Sparke reported an open-market sale of 17,657 shares of common stock at a weighted average price of $5.08 per share. The shares were sold under an irrevocable “sell to cover” provision to satisfy tax withholding on partially vesting RSUs and are described as non-discretionary.
The filing notes the trades occurred at prices ranging from $5.02 to $5.08 per share. Following this tax-related sale, Astley-Sparke directly holds 1,412,414 shares of Replimune common stock.
Replimune Group, Inc. director and Chief Executive Officer Sushil Patel reported selling 37,324 shares of common stock at a weighted average price of $5.08 per share. According to the disclosure, the shares were sold solely to cover tax withholding obligations from the partial vesting of his Restricted Stock Units.
The sales occurred in multiple transactions at prices ranging from $5.01 to $5.08 per share under an irrevocable “sell to cover” provision in the RSU award agreements, described as non-discretionary. Following these transactions, Patel directly holds 747,492 shares of Replimune common stock.
Replimune Group, Inc. Chief Financial Officer Emily Luisa Hill reported an open-market sale of 7,812 shares of common stock. The shares were sold at a weighted average price of $5.08 per share to cover tax withholding obligations tied to the partial vesting of her Restricted Stock Units.
The sale was executed under an irrevocable “sell to cover” provision in the RSU award agreements and is described as not representing a discretionary sale by the reporting person. After these transactions, she directly holds 236,556 shares of Replimune common stock.
Replimune Group, Inc. ownership update: RTW Investments, LP and Roderick Wong report beneficial ownership of 7,356,916 shares, representing 8.9% of the class. The filing cites 82,572,619 Shares outstanding as of January 30, 2026. The Reporting Persons disclose shared voting and shared dispositive power over those shares.
Replimune Group, Inc. Schedule 13G discloses that Suvretta Capital Management, LLC and affiliated reporting person Aaron Cowen each report beneficial ownership of 4,221,836 shares of Replimune common stock, representing 5.1% of the class.
The filing states the shares are owned by advisory clients of Suvretta, with shared voting and dispositive power of 4,221,836 shares and no sole voting or dispositive power. The reporting persons disclaim beneficial ownership except to the extent of pecuniary interest.
Replimune Group amended a Schedule 13G/A to report that T. Rowe Price Associates, Inc. beneficially owns 157,965 shares of Replimune common stock, representing 0.2% of the class. The filing states T. Rowe Price has sole voting power over 152,716 shares and sole dispositive power over 157,965 shares. The filer affirms this ownership disclosure while also denying beneficial ownership in a boilerplate statement.
Replimune Group, Inc. reported that the U.S. Food and Drug Administration issued a second Complete Response Letter for its Biologics License Application for RP1 in combination with nivolumab for treating advanced melanoma.
The company states that, without timely accelerated approval, continued development of RP1 will not be viable and it will eliminate jobs, including substantially scaling back its U.S.-based manufacturing operations. This follows data from the IGNYTE trial where patients with advanced melanoma progressing on prior anti-PD-1 therapy receiving RP1 plus nivolumab showed a 34% response rate with a median response duration of 24.8 months and a favorable safety profile.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
Replimune Group, Inc. disclosed a compensation-related grant of 44,500 non-qualified stock options to director Michael Goller, a full-time employee of Baker Bros. Advisors LP. The options are exercisable into Common Stock at a $7.61 strike price, vest on April 1, 2027 subject to continued board service or a change in control, and expire on April 1, 2036. Baker Bros. Advisors has voting and dispositive power over these options, while affiliated Baker Bros. funds and principals hold only an indirect pecuniary interest and expressly disclaim beneficial ownership beyond that interest. The same 44,500-option grant is reported for each fund that shares this indirect interest.
Replimune Group, Inc. disclosed that Chief Commercial Officer Christopher Sarchi received new equity awards as part of his compensation. He was granted employee stock options for 75,000 shares of common stock at an exercise price of $7.61 per share, vesting 25% on April 1, 2027 and monthly thereafter until fully vested. He also received 50,000 restricted stock units (RSUs), each representing one share of common stock, vesting 25% on May 15, 2027 and then in three approximately equal annual installments through May 15, 2030, subject to continued service. Following these awards, he directly holds 201,588 shares of common stock. These are compensation grants, not open‑market purchases or sales.